This page on Leucine is currently marked as in-progress. We are still compiling research.
Leucine is one of the three Branched Chain Amino Acids and sometimes referred to as the 'main' amino acid due to the most popular benefit of BCAAs (muscle building) being mostly due to leucine. Leucine is an activator of the protein known as mTOR, which then induces muscle protein synthesis via S6K; the other two BCAAs may also activate mTOR, but are much weaker than leucine in doing so (and as such, 5g of leucine will be more effective than 5g mixed BCAAs). The leucine metabolite, HMB, is also weaker than leucine at inducing muscle protein synthesis despite being more effective at preserving lean mass from breakdown.
Leucine is a tad different from the other two BCAAs Isoleucine and Valine as leucine seems to have a fair bit of testing on the amino acid in isolation rather than in a BCAA mixture, whereas the other two BCAAs are not as well studied.
The studies assessing leucine mostly look at muscle protein synthesis when additional leucine is added to the diet or to a test meal, and it appears that leucine is able to reliably increase muscle protein synthesis after test meals. Whether this results in more lean mass over a period of time is somewhat less reliable though, and leucine appears to be more effective at promoting gains in muscle in people with lower dietary protein intake and in the elderly (who tend to have impaired muscle protein synthesis in response to the diet).
The interactions of leucine on glucose are not clear, to be honest. Leucine possesses both blood sugar reducing properties (can release insulin from the pancreas, can directly stimulate glucose uptake into a cell without insulin) but also the opposite (via stimulating S6K, it can inhibit insulin-stimulated glucose uptake). In a cell culture, leucine stimulates glucose uptake for up to 45 minutes and then hinders itself while in living systems acute doses of leucine do not appear to do anything remarkable (some limited evidence that leucine can be rehabilitative in diabetes, but this is preliminary). Isoleucine is a more potent hypoglycemic agent, but to less inhibition of its own actions.
Leucine tends to be supplemented in the 2,000-5,000mg range for acute usage.
It tends to be taken either in a fasted state or alongside meals with an inhernetly low protein content (or protein sources that are low in leucine).
The Human Effect Matrix looks at human studies (excluding animal/petri-dish studies) to tell you what effect Leucine has in your body, and how strong these effects are.
|Grade||Level of Evidence|
|A||Robust research conducted with repeated double blind clinical trials|
|B||Multiple studies where at least two are double-blind and placebo controlled|
|C||Single double blind study or multiple cohort studies|
|D||Uncontrolled or observational studies only|
Level of Evidence
||Magnitude of Effect Size
|C||Rate of Perceived Exertion||
Leucine (also known as 2-Amino-4-methylpentanoic acid) is an essential amino acid of the Branched Chain Amino Acids class (alongside Isoleucine and Valine). Of the three amino acids, leucine stands out for being the most potent activator of a protein known as mTOR (its activation is able to positively influence muscle protein synthesis) and also being an exclusively ketogenic amino acid (producing ketone bodies after catabolism) whereas valine is glucogenic (produced glucose) and isoleucine is both.
Leucine is one of the branched chain amino acids, sometimes referred to as the main BCAA. It is the most potent inducer of muscle protein synthesis on a molecular level, and is ketogenic (produced ketones when metabolized)
Leucine is reversibly metabolized in the body first by the branched-chain aminotransferase enzyme (BCAT) into the intermediate known as α-Ketoisocaproic acid (KIC). KIC can be metabolized into a few intermediates, either β-hydroxyisovalerate (via the mitochondrial KIC dioxygenase enzyme), into isovaleryl-CoA (via branched-chain α-keto acid dehydrogenase (BCKDH)) or into HMB (via the cytosolic KIC dioxygenase enzyme); the last route of metabolism into HMB is approximately 5% of ingested leucine and the only source of HMB in the body.
The first route that converts α-Ketoisocaproic acid (KIC) into β-hydroxyisovalerate can also convert KIC into the metabolite known as α-hydroxycaproic acid (Leucic Acid or HICA).
Leucine is metabolized into one of several metabolites which may contribute to the effects of leucine. Of these, two of them are standalone supplements (HMB and HICA)
The primary mechanism of action from leucine is activation of Target of Rapamycin (TOR) which is referred to as mTOR in mammals (specifically, leucine activates mTORc1 which is one of two subsets of the complex).
The first complex (mTORc1) is a complexation of a few proteins; TOR itself alongside the regulatory associated protein of TOR (Raptor), G-protien β-subunit like protein (GβL), and proline-rich PKB/Akt substrate of 40kDa (PRAS40). This complex is activated by leucine supplementation, whereas the other complex (containing another regulatory protein of TOR known as Rictor and its own regulatory protein known as Proctor, GβL again, and a protein known as mSin1) is not activated by leucine.
TOR, or mammalian TOR (mTOR) is a protein complex that serves a pivotal role in regulating cellular signalling. Leucine is able to activate one of the two complexes it makes up, known as mTORc1 (c1 standing for 'complex one'). When mTOR is mentioned in this article, it is shorthand for mTORc1 unless otherwise specified
Although signalling via the insulin receptor is able to stimulate mTOR (via class 1 PI3K and Akt/PKB, which activate Rheb and mTOR) mTOR from leucine appears to due to a protein officially known as human vacuolar protein sorting 34 (hVPS34) but sometimes colloquiolly referred to as PI3K class 3
hVPS34 depletion is known to blunt leucine-induced mTOR activation while not hindering insulin-induced Akt activation. Incubation of a cell with leucine actiates mTOR without activating Akt and this effect is very similar to a general increase in intracellular calcium; interestingly, leucine seems to induce mTOR activity via increasing intracellular calcium, as the increase in calcium and the binding of calmodulin (a protein involved in calcium homeostasis) to hVPS34 are vital to leucine-induced mTOR activation.
There is a protein known as SHP-2 (a tyrosine phosphatase) which is critical to muscle protein synthesis and is known to limit muscle growth under periods of nutrient deprivation, and it appears to signal to S6K1 via mobilizing intracellular calcium at a point upstream of upstream of phospholipase C β4 and seems to work via Rheb protein stimulation of mTOR, Rheb proteins are known to be positive modulators of mTOR function inherently.
Leucine and/or its metabolites appear to increase intracellular calcium, similar to muscle contractions, and the increase in calcium will activate proteins such as mTOR which then induce muscle protein synthesis. Unlike muscle contraction, however, leucine likely does this in all cells rather than localized to skeletal muscle
In other words: SHP-2 (currently the furthest far back in the chain) -> calcium mobilization -> hVPS34 binding to calmodulin -> mTORc1 activation (possibly via Rheb) -> S6K1 activation -> muscle protein synthesis
Hyper(aminoacid)emia is a term used to refer to an excess (hyper-) of amino acids in the blood (-emia), and similar to that hyperleucinemia refers to an excess of leucine in particular.
In older men, leucine has been found to increase muscle protein synthesis independent of hyperaminoacidemia suggesting it itself is an independent predictor of muscle protein synthesis.
Sirtuin proteins (SIRT being an acronym for Silent Information Regulator Transcript) are NAD+ dependent enzymes that are sensitive to a cellular NAD+/NADH ratio and thus energy status of a cell. Of these, SIRT1 is a histone deacetylase that can modify signalling of the nuclear proteins p53, NF-κB and FOXO and can induce the mitochondrial biogenesis factor PGC-1α. Activation of SIRT1 (the molecule most commonly said to do this is Resveratrol) is thought to be a pro-longevity mechanism.
Leucine is thought to underlie the health benefits of dairy proteins on lifespan which have independently been shown to promote health and reduce the risk of premature death in rats. Serum taken from patients consuming a dairy-rich diet has been shown in vitro to stimulte SIRT1 activity by 13% (adipose) and 43% (muscle tissue), suggesting biological plausibility.
Both leucine metabolites (α-Ketoisocaproic acid and HMB) are activators of SIRT1 in the range of 30-100%, which is a comparable potency to resveratrol (2-10μM) but requires a higher concentration (0.5mM). Mitochondrial biogenesis has been noted with leucine incubation in both fat and muscle cells, and abolishing SIRT1 attenuates (but does not eliminate) leucine-induced mitochondrial biogenesis.
Leucine metabolites are able to stimulate SIRT1 activity, which is a mechanism thought to underlie mitochondrial biogenesis. It is actually moderately potent at doing so
Leucine has potential to promote insulin-induced activation of Akt, but it requires PI3K to be inhibited or suppressed first (and then leucine preserves insulin-induced Akt activation). Due to leucine also stimulating insulin secretion from the pancreas (insulin then activates PI3K) this is likely not practically relevant.
Otherwise, in conditions where insulin is not present 2mM leucine and (to a lesser degree) its metabolite α-ketoisocaproate appear to promote glucose uptake via PI3K/aPKC (atypical PKC) and indepedent of mTOR (blocking mTOR does not alter the effects). This study noted stimulation only at 2-2.5mM for 15-45 minutes (resistance developed at 60 minutes) and was comparable in potency to physiological concentrations of basal insulin but underperformed (50% as potent) as 100nM insulin. This mechanism of action is similar to Isoleucine and appears to be of somewhat similar potency.
However, leucine is also able to hinder cellular glucose uptake which is thought to either be related to activation of mTOR signalling which naturally suppresses AMPK signalling (AMPK signalling being one that mediates glucose uptake during periods of low cellular energy and exercise) in combination with mTOR signalling acting on S6K; signalling via mTOR/S6K will cause degradation of IRS-1 (the first protein that carries the 'signal' of insulin-induced effects) via activating proteasomal degradation of IRS-1 or simply directly binding to IRS-1, this forms a negative feedback control loop of insulin signalling. Inhibiting the negative effects on IRS-1 promotes leucine-induced glucose uptake and this negative feedback explains why glucose is taken up for 45-60 minutes and then suddenly inhibited. Since isoleucine is less potent at activating mTOR and thus this negative feedback pathway, isoleucine but not leucine leads to appreciable glucose uptake in muscle cells.
Leucine appears to initially promote glucose uptake into muscle cells for about 45 minutes, and then cuts itself off which reduces overall effects somewhat. The 'cut off' is a negative feedback that normally occurs after mTOR activation. Isoleucine is better than leucine at promoting glucose uptake due to less activation of mTOR
Leucine, via its metabolite KIC, is able to induce insulin secretion from the pancreas and this insulin release is suppressed by both other BCAAs and two similar branched amino acids (norvaline and norleucine). The potency at 10mM is approximately 73% that of glucose.
In general, leucine is either additive or synergistic with glucose in inducing insulin secretion (for example, a 170% and 240% increase seen with leucine and glucose respectively is increased to 450% with the combination). Despite leucine and Yohimbine being of comparable potencies, they are not additive due to having overlapping mechanisms.
Leucine is known to stimulate insulin secretion from the pancreas, and appears to be the most potent BCAA at doing this. On a equimolar basis (same concentration of the molecule within a cell), leucine is approximately as potent as yohimbine but about two-thirds as potent as glucose itself
Leucine is a positive allosteric regulator of glutamate dehydrogenase (GDH), an enzyme that can convert some amino acids into α-ketoglutarate. This conversion increases cellular ATP concentrations (relative to ADP), and the increase in ATP levels causes an increase in insulin secretion by mechanisms that are independent of mTOR activation.
The metabolite KIC is able to both inhibit KATP channels and trigger calcium oscillations in pancreatic β-cells. The calcium release can further act upon mTOR (standard target of leucine) and activation of mTOR can suppress the expression of α2A receptors. Since α2A receptors are suppressors of insulin release when activated and overexpression induced diabetes, less expression of these receptors causes a relative increase in insulin secretion. This pathway is likely the more important one from a practical standpoint, since the mTOR antagonist rapamycin is able to abolish leucine-induced insulin secretion and suppress insulin secretion by itself.
Leucine works via two pathways to stimulate insulin secretion from pancreatic beta-cells, but the major pathway appears to be due to reducing the influence of a negative regulator (α2A receptors). Reducing a negative regulator's influence causes a refractory increase in activity
Leucine's primary mechanism of action is stimulating the activity of mTOR which then stimulates the activity of p70S6K via PDK1 and p70S6K then positively controls muscle protein synthesis. Furthermore, leucine is able to induce activity of the eukaryotic initiation factor (eIF, specifically eIF4E) and suppresses its inhibitory binding protein (4E-BP1) which enhances protein translation and has been confirmed following oral intake of leucine. Modulation of eIF in this manner enhances muscle protein synthesis induced by p70S6K, and mTOR activation is a common anabolic pathway that is also tied into exercise (not activated acutely, but after a 1-2 hour time delay), insulin, and a caloric excess.
Similar to the other Branched Chain Amino Acids and different than insulin, leucine does not stimulate Akt/PKB activity (which is between the insulin receptor and mTOR, Akt and Protein Kinase B/PKB are interchangeable terms). Akt is able to enhance eIF2B which also positively promotes muscle protein synthesis induced by p70S6K and as such the lack of activation of Akt by leucine is theoretically less potent than if Akt signalling was also promoted like insulin.
mTOR activation from leucine has been confirmed in the tissue of humans following oral supplementation as well as p70S6K activation. Akt activation has been investigated, and there has been a failure to find any alteration in activity in human muscle which suggests that the release of insulin from the pancreas induced by leucine (noted to occur in humans and insulin activates Akt) may not be relevant.
Leucine is able to stimulate mTOR activity and its subsequent protein synthesis signalling. Although Akt/PKB positively influences mTOR activity (so when Akt is activated, it activates mTOR) leucine appears to work via a different pathway and activate mTOR without affecting Akt. Regardless, anything that activates mTOR will then activate p70S6K and then promote muscle protein synthesis
This anabolic effect of leucine appears to favor skeletal muscle more than hepatic (liver) tissue and appears to be augmented by physical exercise (muscle contractions) with some studies suggesting preloading leucine to a workout is more effective than other times (in acutely increasing protein synthesis).
Leucine appears to be the most potent of all amino acids in stimulating muscle protein synthesis.
Leucine is known to promote muscle protein synthesis at low concentrations in vitro while requiring higher concentrations to attenuate atrophy, despite synthesis rates plateuing.
This muscle preserving effect has been noted in disease states characterized by muscular wasting such as cancer as well as sepsis, burns, and trauma. In these scenarios the benefits appear to be dose-dependent.
Hyper(aminoacid)emia is a term used to refer to an excess (hyper-) of amino acids in the blood (-emia), and similar to that hyperleucinemia refers to an excess of leucine in particular.
In older men, leucine has been found to increase muscle protein synthesis independent of hyperaminoacidemia.
Sarcopenia is characterized by a decrease in skeletal muscle mass protein content and an increase in skeletal muscle fat content that occurs with aging. One of the reasons as to why sarcopenia may occur is due to a decrease in the metabolic response to L-Leucine's muscle preserving effects that occurs with cellular aging. This effect can be negated in part by the addition of L-Leucine to protein containing foods.
When the insulin receptor is activated, it can activate mTOR vicariously through Akt. While Akt positively influences protein synthesis induced by S6K1 (which is activated when mTOR is activated), leucine supplementation does not appear to directly activate Akt like insulin does in vitro. Leucine infusions in humans have been noted to not activate Akt significantly in skeletal muscle which suggests that the insulin secretion induced by leucine is insufficient to stimulate Akt.
Leucine has been found to work synergistically with ingested glucose in reducing blood glucose secondary to releasing more pancreatic insulin secretion. Interestingly, leucine is not additive with Yohimbine in inducing insulin secretion due to overlapping mechanisms.
Leucine appears to be synergistic with dietary carbohydrate in promoting insulin secretion from the pancreas, and appears to be synergistic with insulin in promoting muscle protein synthesis
Resveratrol is a wine phenolic that is known to interact with sirtuin proteins (mostly SIRT1) which is similar to leucine; the metabolites of KIC and HMB at 0.5mM are able to induce SIRT1 to 30-100% of baseline which is a comparable potency to 2-10μM resveratrol although the combination of leucine (0.5mM) or HMB (0.5μM) and resveratrol (200nM) is able to synergistically induce SIRT1 and SIRT3 activity in both adipocytes and skeletal muscle cells. KIC appears to be a more potent stimulator than HMB, and synergism appears to be greater with leucine than with HMB (possibly indicative of KIC metabolism).
When rats are fed the combination of leucine (24g/kg, up to 200% of the control diet) or HMB (2 or 10g/kg) with resveratrol (12.5 or 225mg/kg) and then sacrificed in a fasted state, the reductions in fat mass and body weight appear to also be synergistic.
It has been noted that incubation of resveratrol with leucine or HMB actually increases AMPK activity (42-55%, respectively) and promoted a modest (18%) increase in fat oxidation despite incubation with 5mM glucose.
Resveratrol and leucine both appear to positively influence mitochondrial biogenesis via SIRT1 activation, and they both appear synergistic in doing so when incubated or ingested together
Citrulline appears to restore muscle protein synthesis rates and muscular function during aging and malnourishment in rats, and this appears to be mediated via the mTORc1 pathway (abolished by the mTORc1 inhibitor known as rapamycin).
For human studies, supplementation of 0.18g/kg citrulline for a week has failed to significantly modify leucine oxidation rates or whole body protein synthesis but elsewhere at the same dose has been noted to improve nitrogen balance in humans in the fed state. The reason for this discrepancy is unknown.
There is not too much evidence looking at the direct activation of citrulline on mTOR, but it appears to weakly induce proteins after mTOR (including 4E-BP1) to a degree lesser than leucine. It is plausible that citrulline augments mTOR signalling since its benefits are mTOR dependent, in which case it should be synergistic with leucine; this has not been directly investigated.
Citrulline may positively mediate leucine's signalling through mTOR, which theoretically suggests that they are synergistic. The application of the combination towards weight lifters has not yet been investigated, so the synergism is currently just a hypothesis rather than a demonstrated fact
In a small study in 5 healthy men given graded leucine intake up to 1,250mg/kg (25-fold the estimated average requirement) noted that oral doses of 500-1,250 caused increases in serum ammonia and due to this the upper limited was said to be established at 500mg/kg (for a 150lb human, 34g).
(Common misspellings for Leucine include loocine, lucine, leucin)
(Common phrases used by users for this page include how much lucine to get effect, why people take leucine, l-leucine DOSAGE, leucine, leucine, leucine supplementation dose)